SCHEMBL91325

SCHEMBL91325

CCc1ccnc(NCCNC(C)=O)n1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 5/20 0.45
CYP3A4 P08684 4/20 0.45
CLK4 Q9HAZ1 4/20 0.45
HSD17B10 Q99714 3/20 0.45
ALDH1A1 P00352 2/20 0.45
ALOX15 P16050 2/20 0.45
MAPK1 P28482 2/20 0.45
CA12 O43570 1/20 0.44
CA4 P22748 1/20 0.44
CA7 P43166 1/20 0.44
CA9 Q16790 1/20 0.44
CA14 Q9ULX7 1/20 0.44
PDCD1 Q15116 3/20 0.39
CD274 Q9NZQ7 3/20 0.39
MTNR1A P48039 4/20 0.39
MTNR1B P49286 3/20 0.39
ACACB O00763 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
MAPK8 P45983 1/20 0.38
TSHR P16473 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10224750 0.82 HPGD (0.45) CYP1A2HSD17B10ALDH1A1MAPK1NPSR1
SCHEMBL10225052 0.82 CYP1A2 (0.50) CYP1A2CYP3A4CLK4HSD17B10ALDH1A1
SCHEMBL84366 0.78 CYP1A2 (0.44) CYP1A2CYP3A4CLK4HSD17B10ALDH1A1
SCHEMBL10224751 0.78 PLK1 (0.46) CYP1A2CYP3A4CLK4HSD17B10ALDH1A1
SCHEMBL25056999 0.77 ALDH1A1 (0.61) CYP1A2CYP3A4CLK4HSD17B10ALDH1A1
SCHEMBL15601828 0.77 CA12 (0.38) ALOX15CA12CA4CA7CA9
SCHEMBL1089291 0.74 CXCR4 (0.64) ALDH1A1
SCHEMBL15185770 0.71 HRH4 (0.43) ALDH1A1
SCHEMBL13039366 0.71 EIF2AK2 (0.45) CYP1A2CYP3A4CLK4HSD17B10ALDH1A1
SCHEMBL805468 0.70 PDE6D (0.38) CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8129394-B2 Heteroaryl-substituted imidazole compounds and uses thereof NOVARTIS AG (CH) 2012-03-06 US disclosed
US-20100003246-A1 Novel heterocyclic compounds and uses therof NOVARTIS AG (CH) 2010-01-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100003246-A1 Novel heterocyclic compounds and uses therof BRAF, ARAF, KRAS CYP1A2 4611/4885CYP3A4 4401/4885CLK4 974/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.